Available July 1: the first over-the-counter test that offers fast and accurate testing for both COVID-19 and Flu A/B

Beginning July 1, 2024, the LUCIRA by Pfizer COVID-19 & Flu Test will be available to order for all PRN members. This cordless device gives you results in 30 minutes, showing a positive result in as few as 11 minutes.

LUCIRA by Pfizer COVID-19 and Flu A & B test offers the convenience of an in-office test with molecular testing and PCR-quality accuracy for ages 2 and up.

Swab, stir and detect. 3 simple steps with an easy-to-read display. Click on the image below for more details.

Moderna Information to Support Your Immunization Needs

Moderna is here to support your immunization efforts. Ensure your team is ready for the upcoming COVID-19 season by reserving your vaccine supply today.

Click the links below for more information:

2024-2025 Expected Presentation: Moderna COVID-19 Vaccine Pediatric Pre-Book Information (6 months - 11 years of age)

2024-2025 Expected Presentation: Spikevax (COVID-19 Vaccine, mRNA) - 12 years of age and older

Available April 1: The only FDA-approved vaccine that helps prevent all 5 leading types of meningococcal meningitis

Source: www.penbraya.com

PENBRAYA is available for order beginning April 1, 2024.  PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.  PENBRAYA is approved for use in individuals 10 through 25 years of age. 

PENBRAYA combines 2 vaccines that have nearly 10 years of experience to help protect against all 5 leading types of meningitis—A, B, C, W, and Y. Patients can now get the broadest protection against all 5 leading types of meningococcal meningitis with the fewest shots.

Click here for more information.

If you are interested in ordering, please contact Tina Clark, Contract Administrator, at tina@prn-gpo.com or (888)776-2360.

Save 6% now on MenQuadfi® Meningococcal Group A, C, W and Y Conjugate Vaccine

Sanofi is offering a 6% sales promotion on all MenQuadfi® Meningococcal Group A, C, W and Y Conjugate Vaccine orders placed between February 5, 2024 and March 31, 2024. You can schedule MenQuadfi® orders to ship immediately or future ship through October 31, 2024 on VaccineShop.com or VaxServe.com. Scheduling orders now can help you manage your inventory throughout the back-to-school season. 

If you have any additional questions, please feel free to contact a Sanofi representative or call Sanofi’s customer service at 1-800-822-2463.

Empower Your COVID-19 Fight: Essential Vaccine Insights

As we navigate a world where COVID-19 is one of many health concerns, your commitment to patient care remains invaluable. Your expertise and counsel continue to play a crucial role in disease prevention and patient health.

With the number of COVID-19 hospitalizations topping 19,000 the week of November 19 – 25, 2023, vigilance and preventative measures remain essential. The ACIP continues to recommend updated COVID vaccines for all patients aged 6 months and older, and your guidance can make a powerful difference.

To assist you, Moderna has assembled a concise resource that sheds light on the latest research and the importance of extended vigilance in combatting the spread of the SARS-CoV-2 virus.

The role of healthcare professionals is pivotal in guiding vaccine decisions. Studies show that messages involving a personal physician or a scientist recommending vaccination were the most compelling ways to improve vaccine adherence.

We invite you to gain deeper insights into these findings and more by clicking here.

Together, we continue to strive to protect patients from COVID-19. Thank you for your relentless dedication and the difference you make every day.

For inquiries call 1-866-MODERNA (1-866-663-3762).

Pediatric COVID Vaccines Purchased on or After January 9, 2024 Now 100% Returnable

Important Announcement from Moderna:

Moderna is pleased to announce an important update to their vaccine return policy that they hope will have a positive impact on pediatric health and immunization rates.

Effective immediately, all privately purchased pediatric COVID-19 vaccine doses (NDC No. 80777-0287-92) purchased on or after January 9, 2024 will be 100% returnable for the entire season, pursuant to the return policies and procedures provided in your contract with Moderna.

This change is part of Moderna’s commitment to support healthcare providers and ensure that all children under the age of 12 have access to the COVID-19 vaccine.

Moderna understands the challenges faced by providers in predicting the exact number of doses needed. By allowing for increased returnability of unused pediatric COVID-19 vaccines, Moderna aims to eliminate the risk of unused excess supply for providers and encourage them to keep a healthy stock on-hand without the worry of excess inventory.

Let's work together to keep our children safe and healthy.